A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.

Other literature type, Article English OPEN
Durez, P; Nzeusseu, T; Lauwerys, B; Manicourt, D; Verschueren, P; Westhovens, R; Devogelaer, J; Houssiau, F;
(2004)
  • Related identifiers: pmc: PMC1755125, doi: 10.1136/ard.2003.012914
  • Subject: Antibodies, Monoclonal | Extended Report | C-Reactive Protein | Aged | Methylprednisolone | Methotrexate | Middle Aged | Matrix Metalloproteinase 3 | Interleukin-6 | Immunosuppressive Agents | Arthritis, Rheumatoid | Severity of Illness Index | Antirheumatic Agents | Drug Therapy, Combination | Glucocorticoids | Adult | Female | Quality of Life | Single-Blind Method | Humans | Male

OBJECTIVES: To compare the short term clinical and biological effects of intravenous (i.v.) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment. METHODS: Patients with active RA... View more
Share - Bookmark